Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-03-31 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于举行2020年年度业绩网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online performance briefing for the 2020 annual results. It references that the full 2020 annual report has already been published on the official disclosure website. The document invites investors to participate in a webcast with company executives to discuss the annual results. The document itself does not contain the annual report or detailed financial data but is an announcement of an event related to the annual report. The document length is short (705 characters), consistent with an announcement rather than a full report. Therefore, this fits the category of an Investor Presentation (IP) or possibly a Report Publication Announcement (RPA). However, since it is specifically about an online performance briefing (an annual results presentation), the best fit is Investor Presentation (IP).
2021-03-31 Chinese
独立董事关于公司第四届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various company matters discussed at the 13th meeting of the 4th board of directors, including internal control self-evaluation, related party transactions, profit distribution plan, external guarantees, remuneration, related party transactions forecast, audit firm reappointment, and accounting policy changes. It references the 2020 fiscal year and 2021 plans. The document is a formal opinion letter from independent directors, not a full financial report or audit report itself. It does not contain detailed financial statements or comprehensive financial analysis but provides independent opinions on specific governance and financial matters. This type of document aligns with Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on governance and financial issues. The document length is under 5,000 characters and is not a report publication announcement or certification letter but a formal board-related opinion document.
2021-03-31 Chinese
年报披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (441 characters) from a company about the disclosure of its 2020 Annual Report. It states that the full annual report and summary will be published on April 1, 2021, on a regulatory website. The document itself does not contain the annual report or financial data but only informs investors about the upcoming publication. According to the 'MENU VS MEAL' rule, such a brief notice announcing the availability of a report is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2021-03-31 Chinese
独立董事关于公司第四届董事会第十三次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the company's board meeting agenda items, specifically about the reappointment of the 2021 audit firm and approval of related party transactions for 2021. It references regulatory guidelines and internal company rules but does not contain financial statements or detailed audit results. The document is short (653 characters) and serves as a pre-approval or endorsement related to board decisions rather than a full audit report or annual report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board matters and management decisions.
2021-03-31 Chinese
监事2020年薪酬的确定及2021年薪酬方案
Remuneration Information Classification · 95% confidence The document details the remuneration determination for supervisors (监事) for the year 2020 and the remuneration plan for 2021. It includes specific salary figures, payment standards, and references to company governance documents such as the Articles of Association and the remuneration management system. The document also mentions that the remuneration plan requires approval at the 2020 annual shareholders' meeting. This content is focused on compensation information for company directors or supervisory board members, which aligns with the definition of Remuneration Information filings. The document is not an annual report, audit report, or a general announcement but specifically details compensation schemes and amounts for supervisory board members.
2021-03-31 Chinese
监事会对公司2020年度内部控制自我评价报告的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's opinion on the company's 2020 internal control self-evaluation report. It references the internal control report but does not contain the full report itself. The document is short (466 characters) and serves as an official announcement or opinion regarding the internal control report. It does not contain financial statements or detailed financial data. Therefore, it is not the full Annual Report or Audit Report but rather a regulatory announcement related to internal control evaluation. Given the nature and length, it fits best under Regulatory Filings (RNS) as a compliance-related announcement.
2021-03-31 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.